H.C. Wainwright analyst Yi Chen initiated coverage of VolitionRx (VNRX) with a Buy rating and $2.50 price target VolitionRx is a diagnostics company focused on the development of epigenetic tests based on nucleosomes that can enable early detection of diseases including certain cancers and sepsis, the analyst tells investors in a research note. The firm says the company’s Nu.Q diagnostic technology is validated by the commercialized Nu.Q Vet cancer test.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX: